Interim Report, January-March 2006
-Net sales amounted to MSEK 50.3 (1.2) -Profit after tax was MSEK 15.3 (loss: 18.8) -Earnings per share amounted to SEK 1.15 (loss: 2.04) Key events during the first quarter of 2006 -Orexo received its first payment of MSEK 46.6, in January 2006, for the licensing agreement with ProStrakan Group plc relating to Rapinyl™ for the European market. Key events after the close of the period -The subsidiary Kibion AB acquired Noster System AB, with net sales of MSEK 11.4 in 2005. -Increased investment in Sublinox™ (OX 22) for treating sleep disturbances. -On April 27, Orexo held its Annual General